Trial Profile
A Phase III, Double-Blind, Lot-To-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs V 212 (Primary)
- Indications Varicella zoster virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme Corp.
- 29 Aug 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Jul 2014 New trial record